Did you know that BiotechBlog posts are syndicated to outlets such as Reuters, Biospace, San Francisco Gate, Chicago Sun-Times, and dozens of other media outlets? BiotechBlog provides a forum to promote your expertise through the publication of actionable industry guidance. See guest content and the submission guidelines for more information
The Journal of Commercial Biotechnology is looking for papers on investing strategies in the biotechnology space. The scope can include valuation models, strategies to identify under-valued companies, case studies in developing and managing a portfolio, etc.
The Journal of Commercial Biotechnology is a peer-reviewed journal focused on the business of biotechnology. More information, instructions for authors, and a sample issue are available at http://CommercialBiotechnology.com
For those attending BIO2008 in San Diego this year, I’ll be doing a signing of my books on Wednesday June 18th from 10-11. There will also be a limited number of free copies of the Journal of Commercial Biotechnology, so be sure and show up early!
I’ll also be speaking on Friday morning:
Title: Scientific Communications – Trends and Liabilities
Track: Public Relations/Investor Relations
Date and Time: Friday, June 20 9:00 AM – 10:30 AM
Hope to see you there!
I’ve nearly completed revisions for the third edition of Building Biotechnology, the leading textbook on the business of biotechnology. This new edition has several new chapters, new case studies, updated case law, and fresh industry stats — more than 100 pages longer than the second edition.
I’m looking for volunteers to review the chapters and potentially contribute case studies of:
- Career development
- Managing reimbursement
- General management
Reviewers and contributors will be given a free copy of the final edition (an $80 value).
The chapter list is pasted below. If you are interested in reviewing/contributing, please drop me a brief note stating your interest and the chapter(s) you would like to review or contribute to. For an example of previous contributions, see these samples.
1 – Introduction
2 – The Development of Biotechnology
Knowledge and Skills
3 – Introduction to Molecular Biology
Information Flow in Molecular Biology
The Big Picture
4 – Drug Development
Biologic vs. Pharmaceutical Drug Development
The Five Basic Steps of Drug Development
Qualities of a “Good” Drug
5 – Tools and Techniques
6 – Applications
Green Biotechnology: Agriculture
White Biotechnology: Industrial Processes and Bio-based Products
Red Biotechnology: Medical Applications
Laws, Regulations, and Politics
7 – Intellectual Property
When Patents Expire
Patent Infringement, Exemptions, and Licenses
The Role of Intellectual Property in Biotechnology
8 – Regulation
Food and Drug Administration
Department of Agriculture
Environmental Protection Agency
Securities and Exchange Commission
9 – Politics
Balancing Innovation Incentives with Economic Constraints
The Business of Biotechnology
10 – Biotechnology Company Fundamentals
11 – Finance
Development Stages and Funding
Other Funding Sources
12 – Research and Development
13 – Marketing
Marketing as a Guide for R&D
Market Structure and Marketing Environment
Marketing Planning and Strategy
14 – Licensing, Alliances, and Mergers
Licensing and Outsourcing
Mergers and Acquisitions
Selecting Partnership Options
15 – Managing Biotechnology
Intellectual Property Protection
Management Changes with Growth
Dealing with Failure
16 – International Biotechnology
Benchmarking against the United States
Intellectual Property Protection
17 – Building Biotechnology
Selecting Opportunities and Business Planning
18 – Investing
Investing in Biotechnology
19 – Career Development
Ph.D., MBA, or Both?
20 – Final Words
The science of biotechnology is tough. R&D can be unpredictable, and most products need regulatory approval before they can be sold. But biotechnology companies also need to worry about other problems, like management issues. The case of Dyadic’s illustrates some of the often-overlooked challenges in commercializing biotechnology.
Mark Emalfarb founded Dyadic in 1979 as a supplier of tools for stone-washing jeans. When cellulase enyzme technologies for stone-washing emerged, they threatened Dyadic’s use of pumice stones. Rather than fight this change, the company sought to out-innovate early cellulase suppliers and developed a promising fungal expression system with the potential to produce large quantities of complex proteins and enzymes, including cellulase. Opportunities also exist in cellulosic biofuel production and drug manufacturing.
As is often the case in dynamic industries, innovators can be blindsided by unexpected challenges. In spring 2007, Dyadic became aware of operational and financial improprieties at its Asian subsidiaries. An investigation conducted under the supervision of the board of directors audit committee found that Emalfarb had willfully concealed facts relating the improprieties, which led to his termination. [a representative from Dyadic opted not to comment on this case, and instead directed me to their press release archives]. A report detailing their justification for firing Emalfarb does not imply direct malfeasance, but claims that Emalfarb did not take strong-enough action to stop off-the-books and tax-evading transactions.
Emalfarb, who maintains his innocence, is the largest shareholder of Dyadic, and has been fighting to regain control of the firm. In February 2008 Emalfarb and two hedge funds, who collectively own more than 50% of the shares, issued a letter to the company demanding the resignation of the new CEO and two board members. Interestingly, despite the protests of this group representing a controlling share of the company, the battle for control continues.
Sadly, this is a case with no clear winner. Regardless of who will direct the company in the future, the share price has been decimated and growth opportunities have certainly been missed. Rather than focusing on developing applications of Dyadic’s core technologies, the founder and company are engaged in legal battles.
[Update: Emalfarb regained control of the company]
Courtesy of DrugPatentWatch.com:
Drug Patent Expirations in May 2008
*Drugs may be covered by multiple patents
|Tradename||Applicant||Generic Name||Patent Number||Patent Expiration|
|HABITROL||Novartis||nicotine||5,016,652||May 21, 2008|
|REQUIP||Glaxosmithkline||ropinirole hydrochloride||4,824,860||May 19, 2008|
|SARAFEM||Lilly||fluoxetine hydrochloride||4,971,998||May 20, 2008|
Courtesy of DrugPatentWatch.com